Paul Bunn Biography and Net Worth

Director of Verastem

Dr. Bunn is a Distinguished Professor of Medicine and James Dudley Chair in Cancer Research, Division of Medical Oncology at the University of Colorado School of Medicine. Dr. Bunn previously served as section head of the U.S. National Cancer Institute (NCI)-Navy Medical Oncology branch, Head of the Division of Medical Oncology at the University of Colorado, and Director of the University of Colorado Cancer Center.

Dr. Bunn was President of the American Society of Clinical Oncology (ASCO), as well as on its Board of Directors. He was also President of the American Association of Cancer Institutes (AACI) and has chaired the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee. Dr. Bunn served on the Board of Directors, as President and as Chief Executive Officer, of the International Association for the Study of Lung Cancer (IASLC), growing the IASLC to become a highly impactful, multidisciplinary organization that includes researchers and clinicians from all over the world.

Dr. Bunn was also the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by NCI to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention, and treatment. The author of hundreds of articles, reviews and book chapters, Dr. Bunn’s work is credited with setting standards in the treatment of the disease.

What is Paul A. Bunn's net worth?: The estimated net worth of Paul A. Bunn is at least $10.20 thousand as of November 21st, 2025. Bunn owns 2,083 shares of Verastem stock worth more than $10,196 as of March 30th. This net worth estimate does not reflect any other assets that Bunn may own. Learn More about Paul A. Bunn's net worth.
How do I contact Paul A. Bunn?: The corporate mailing address for Bunn and other Verastem executives is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. Verastem can also be reached via phone at (781) 292-4200 and via email at [email protected]. Learn More on Paul A. Bunn's contact information.
Has Paul A. Bunn been buying or selling shares of Verastem?: Paul A. Bunn has not been actively trading shares of Verastem during the past quarter. Most recently, Paul A. Bunn sold 6,250 shares of the business's stock in a transaction on Friday, November 21st. The shares were sold at an average price of $10.00, for a transaction totalling $62,500.00. Following the completion of the sale, the director now directly owns 2,083 shares of the company's stock, valued at $20,830. Learn More on Paul A. Bunn's trading history.
Who are Verastem's active insiders?: Verastem's insider roster includes Paul Bunn (Director), Daniel Calkins (CFO), Robert Gagnon (CFO), Michael Kauffman (Director), Dan Paterson (COO), and Brian Stuglik (CEO). Learn More on Verastem's active insiders.
Are insiders buying or selling shares of Verastem?: In the last twelve months, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 158,578 shares worth more than $1,283,762.25. The most recent insider tranaction occured on February, 4th when CEO Dan Paterson sold 970 shares worth more than $6,489.30. Insiders at Verastem own 2.1% of the company. Learn More about insider trades at Verastem.
Information on this page was last updated on 2/4/2026.

Paul A. Bunn Insider Trading History at Verastem

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/21/2025	Sell	6,250	$10.00	$62,500.00	2,083
10/9/2025	Sell	8,333	$9.06	$75,496.98	8,333

Paul A. Bunn Buying and Selling Activity at Verastem

Verastem Company Overview

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Today's Range

Now: $4.84

$4.80

$5.09

50 Day Range

MA: $6.00

$4.93

$6.79

2 Week Range

Now: $4.84

$4.01

$11.24

Volume

1,357,857 shs

Average Volume

1,927,028 shs

Market Capitalization

$424.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4